Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001567619-21-021392)

Filing Details

Accession Number:: 0001567619-21-021392
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-01 17:01:23
Reporting Period:: 2021-11-29

Accepted Time:: 2021-12-01 17:01:23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1389046	F James Polewaczyk	One Idexx Drive Westbrook ME 04092	Executive Vice President	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-11-29	4,595	$633.00	14,818	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

Updated to correct a scrivener's error in the Form 4 filed on August 25, 2021, which inadvertently reported the total amount of beneficially owned securities following the reported transaction as 19,494.2845 instead of 19,404.2845. Also includes 9 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2021.